Novel oral anticoagulants for stroke prevention in atrial fibrillation: Results of the European Heart Rhythm Association survey

Europace

Volumn 15, Issue 10, 2013, Pages 1526-1532

  Lip, Gregory Y H ^a   Bongiorni, Maria Grazia ^b   Dobreanu, Dan ^c   Lewalter, Thorsten ^d   Hastrup Svendsen, Jesper ^e,f   Blomström Lundqvist, Carina ^g  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d Isarklinikum Munich   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f DANISH NATIONAL RESEARCH FOUNDATION   (Denmark)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulation; Apixaban; Atrial fibrillation; Dabigatran; EHRA survey; EP wire; Guidelines; New oral anticoagulants; Rivaroxaban; Stroke; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; DIPYRIDAMOLE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLEEDING; CARDIOVASCULAR RISK; CARDIOVERSION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG PREFERENCE; EMERGENCY SURGERY; HEALTH CARE SURVEY; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEMODIALYSIS; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; REVIEW;

ANTICOAGULATION; APIXABAN; ATRIAL FIBRILLATION; DABIGATRAN; EHRA SURVEY; EP WIRE; GUIDELINES; NEW ORAL ANTICOAGULANTS; RIVAROXABAN; STROKE; WARFARIN;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DRUG MONITORING; DRUG UTILIZATION REVIEW; EUROPE; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HEMORRHAGE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885002061     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut292     Document Type: Review

References (34)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: developed with the special contribution of the European Heart RhythmAssociation. Europace 2012;14:1385-413.
2. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012;107:584-9.
3. Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart survey. Thromb Haemost 2013;109:328-36.
4. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
5. Lip GY. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol 2011;8:602-6.
6. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation Cohort Study. Eur Heart J 2012;33:1500-10.
7. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G et al. Questions and answers on the use of dabigatran and perspectiveson the use of other neworal anticoagulants in patients with atrial fibrillation.Aconsensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106:868-76.
8. Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-47.
9. Turpie AG, Kreutz R, Llau J, Norrving B, Haas S. Management consensus guidance for the use of rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2012; 108:876-86.
10. Heidbuchel H, Verhamme P, Alings M, Antz M, HackeW, Oldgren J et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
11. Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 2011;140:911-7.
12. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart survey on atrial fibrillation. Am Heart J 2007;153:1006-12.
13. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart survey on atrial fibrillation. Chest 2010; 137:263-72.
14. LipGY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J 2013;34:1041-9.
15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart survey. Chest 2010;138:1093-100.
16. Omran H, Bauersachs R, Rubenacker S, Goss F, Hammerstingl C. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER). Thromb Haemost 2012;108:65-73.
17. Fitzmaurice DA, Murray ET, McCahon D, Holder R, Raftery JP, Hussain S et al. Self management of oral anticoagulation: randomised trial. BMJ 2005;331:1057.
18. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, AikensTH et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-6.
19. Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, SingerDE et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET-AF trial. J Am Coll Cardiol 2013;61:1998-2006.
20. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15: 1407-11.
21. Bin Abdulhak AA, Khan AR, Tleyjeh IM, Spertus JA, Sanders SU, Steigerwalt KE et al. Safety and efficacy of interrupted dabigatran for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Europace 2013;15:1412-20.
22. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011;106:572-84.
23. Huber K, Airaksinen KJ, Cuisset T, Marin F, Rubboli A, Lip GY. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106:569-71.
24. Eikelboom JW,Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Longterm anticoagulant therapY (RE-LY) trial. Circulation 2011;123:2363-72.
25. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-term anticoagulation therapY (RE-LY) trial. Circulation 2013;127:634-40.
26. Dewilde WJ, Oirbans T, VerheugtFW, Kelder JC, De Smet BJ, Herrman JP et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;381:1107-15.
27. Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013;62: 981-9.
28. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, RosenzweigMet al. Efficacy and safety of dabigatran etexilate and warfarin in 'real world' patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61: 2264-73.
29. Hohnloser SH, Oldgren J, Yang S,Wallentin L, Ezekowitz M, Reilly P et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-term anticoagulation therapY) trial. Circulation 2012;125:669-76.
30. Ogilvie IM, Newton N,Welner SA, CowellW, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123:638-45 e634.
31. Kansal AR, Sharma M, Bradley-Kennedy C, Clemens A, Monz BU, Peng S et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 2012;108:672-82.
32. Kansal AR, Sorensen SV, Gani R, Robinson P, Pan F, Plumb JM et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart 2012;98:573-8.
33. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT2R2 (sex female, age less than 60, medical history, treatment strategy [rhythm control], tobaccouse [doubled], race [doubled] score.Chest 2013;DOI: 10.1378/chest.13-0054.
34. Marlu R, Hodaj E, Paris A, Albaladejo P, Crackowski JL, Pernod G. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108:217-24.